Roth Capital affirms Cytori Therapeutics (Nasdaq: CYTX) at Buy with a target price of $3.50 following news that it and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE